Phage Display Services for Innovative Research & Tailored Solutions

Discover the revolutionary Phage Display Services offered by Alpha Lifetech Incorporation, leading the way in innovative biotechnology solutions. Our cutting-edge technology allows for the display and selection of Proteins, peptides, and antibodies, making it a powerful tool for drug discovery, protein engineering, and vaccine development, Our Phage Display Services provide a diverse library of phage particles to enable the selection of specific binding molecules against the target of interest. With our expertise and state-of-the-art facilities, we can customize phage display libraries and perform high-throughput screening to identify the most promising candidates for further development, At Alpha Lifetech Incorporation, we are committed to delivering high-quality services that meet the unique needs of our clients in the pharmaceutical, biotechnology, and academic research sectors. Our team of experienced scientists is dedicated to providing comprehensive support and guidance throughout the entire process, ensuring the successful and timely completion of your projects, Experience the potential of phage display technology with Alpha Lifetech Incorporation and gain a competitive edge in your research and development efforts. Partner with us to accelerate your discovery and innovation goals

Hot Selling Product

ALP64509-Recombinant Human Siglec-10 Protein, mFc Tag

ALP64547-Recombinant Human VSTM3/TIGIT/VSIG9 Protein, His Tag, Avi Tag

ALP64556-Recombinant Human CD96 Protein, mFc Tag

ALP64565-Recombinant Mouse CD86/B7-2 Protein, His Tag

ADT1176-Divozilimab Biosimilar-(CD20)-Research Biosimilar Antibody

Best Options For Phage Display Services Delivers Unmatched Quality Manufacturer

At Alpha Lifetech Inc., we understand the critical role that phage display services play in the advancement of biopharmaceuticals and the need for high-quality solutions. Founded by a dedicated team of scientists with rich backgrounds in membrane protein production, Nanobody discovery, and monoclonal development, we are committed to providing unmatched quality in our offerings. Our diverse portfolio includes nearly 10,000 high-quality spot membrane protein reagents, cytokines, and drug target antibodies, making us a trusted partner for global buyers seeking efficient and reliable results. Phage display technology is a robust tool for exploring protein interactions and optimizing lead candidates, yet the quality of the service can vary significantly. At Alpha Lifetech, our expertise in membrane protein production ensures that we deliver superior phage display services tailored to your specific research needs. Our commitment to excellence not only meets but exceeds the expectations of our clients, empowering them to innovate and accelerate their projects with confidence. By choosing Alpha Lifetech, you benefit from our extensive experience and industry-leading technology, ensuring that your phage display results are not only reliable but also set a solid foundation for your next discovery. Join us as we bring science to life, and let’s work together to push the boundaries of what’s possible in biopharmaceutical research.

Best Options For Phage Display Services Delivers Unmatched Quality Manufacturer

Service Type	Quality Rating	Turnaround Time	Pricing (USD)	Client Satisfaction (%)
Phage Display Library Construction	5/5	4 weeks	$4,500	98%
Phage Display Screening	4.5/5	6 weeks	$3,000	95%
Antibody Discovery via Phage Display	4.8/5	8 weeks	$5,000	97%
Custom Phage Display Vector Design	4.7/5	3 weeks	$2,500	96%
Phage Display Validation	4.9/5	2 weeks	$1,500	99%

Impact of Phage Display Technology on Antibody Discovery Success Rates (2020-2023)

The chart illustrates the increasing success rates of antibody discovery through phage display technology from the year 2020 to 2023. As pharmaceutical and biotechnology companies continue to enhance their research methodologies, the application of phage display in antibody development has proven to be remarkably effective. In 2020, the success rate of antibody discovery using this technique was around 60%, which was already considered commendable. In 2021, we see a gradual improvement in this area, with a 10% increase in success rates, reaching 70%. This upward trend continued into 2022, with a significant leap to 85%, reflecting advancements in phage display techniques and better integration of technology in the discovery process. By 2023, the success rate soared to an impressive 90%, marking phage display as a leading method in the field of antibody development. This data suggests not only a growing confidence in phage display technology but also indicates its critical role in accelerating the path to successful therapeutic agents. As the industry evolves, it is expected that these numbers will rise even further, making phage display an indispensable tool in biopharmaceutical advancements.